Roland A Ammann1, Franziska Zucol2, Christoph Aebi3, Felix K Niggli4, Thomas Kühne5, David Nadal2. 1. Pediatric Hematology/Oncology, Department of Pediatrics, University of Bern, CH-3010, Bern, Switzerland. roland.ammann@insel.ch. 2. Division of Infectious Diseases, University Children's Hospital, University of Zurich, Zurich, Switzerland. 3. Institute of Infectious Diseases, University of Bern, Bern, Switzerland. 4. Division of Oncology, University Children's Hospital, University of Zurich, Zurich, Switzerland. 5. Pediatric Hematology/Oncology, University Children's Hospital, University of Basel, Basel, Switzerland.
Abstract
MATERIALS AND METHODS: In a pilot study, results of real-time broad-range (16S rRNA) polymerase chain reaction (PCR) performed on 45 blood samples of pediatric cancer patients with fever and neutropenia were compared with blood culture results. RESULTS: The PCR assay used, having proven a high sensitivity in artificially spiked blood samples, was positive in only three of ten blood culture-positive samples, and it was positive in 10 of 35 (29%) culture-negative samples. CONCLUSION: This broad-range PCR assay, which may identify not-grown bacteria potentially contributing to fever, needs improvement in sensitivity, and different reasons for positive PCR in negative blood culture samples need to be assessed before clinical application.
MATERIALS AND METHODS: In a pilot study, results of real-time broad-range (16S rRNA) polymerase chain reaction (PCR) performed on 45 blood samples of pediatric cancer patients with fever and neutropenia were compared with blood culture results. RESULTS: The PCR assay used, having proven a high sensitivity in artificially spiked blood samples, was positive in only three of ten blood culture-positive samples, and it was positive in 10 of 35 (29%) culture-negative samples. CONCLUSION: This broad-range PCR assay, which may identify not-grown bacteria potentially contributing to fever, needs improvement in sensitivity, and different reasons for positive PCR in negative blood culture samples need to be assessed before clinical application.
Authors: Remco P H Peters; Michiel A van Agtmael; Sven A Danner; Paul H M Savelkoul; Christina M J E Vandenbroucke-Grauls Journal: Lancet Infect Dis Date: 2004-12 Impact factor: 25.071
Authors: Franziska Zucol; Roland A Ammann; Christoph Berger; Christoph Aebi; Martin Altwegg; Felix K Niggli; David Nadal Journal: J Clin Microbiol Date: 2006-08 Impact factor: 5.948
Authors: Philipp Peter Bosshard; Andreas Kronenberg; Reinhard Zbinden; Christian Ruef; Erik Christian Böttger; Martin Altwegg Journal: Clin Infect Dis Date: 2003-07-09 Impact factor: 9.079
Authors: Marie von Lilienfeld-Toal; Lutz E Lehmann; Ansgar D Raadts; Corinna Hahn-Ast; Katjana S Orlopp; Günter Marklein; Ingvill Purr; Gordon Cook; Andreas Hoeft; Axel Glasmacher; Frank Stüber Journal: J Clin Microbiol Date: 2009-07-01 Impact factor: 5.948
Authors: Yanan Zhao; Steven Park; Barry N Kreiswirth; Christine C Ginocchio; Raphaël Veyret; Ali Laayoun; Alain Troesch; David S Perlin Journal: J Clin Microbiol Date: 2009-04-29 Impact factor: 5.948
Authors: Peter Paul C Lim; Lisa M Stempak; Sindhoosha Malay; LeAnne N Moore; Sree Sarah S Cherian; Ankita P Desai Journal: Antibiotics (Basel) Date: 2022-01-26
Authors: Olaf Penack; Carolin Becker; Dieter Buchheidt; Maximilian Christopeit; Michael Kiehl; Marie von Lilienfeld-Toal; Marcus Hentrich; Marc Reinwald; Hans Salwender; Enrico Schalk; Martin Schmidt-Hieber; Thomas Weber; Helmut Ostermann Journal: Ann Hematol Date: 2014-04-29 Impact factor: 3.673